Endometrial Carcinoma Clinical Trial
Official title:
A Preoperative "Window-opportunity", Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma
The primary objective of this study is to identify, in human tumour samples, biomarker changes associated to short exposure to AZD2281 as potential predictors of activity in Endometrial Carcinoma (EC). This is an exploratory study with a biological primary endpoint. Clinical efficacy or safety are not a primary objective of the study.
The main objective of the present proposal study is to assess the biological consequences of PARP inhibition in type I primary EC, in patients who receive therapy with AZD2281 during the period of time between diagnosis and surgery. This is a phase 0 trial or "Exploratory Investigational New Drug" study, a type of trial that involves limited number of patient under drug therapy and has no therapeutic or diagnostic intent because the drug exposure has a limited duration and the dosage is lower than 100% of the dose required to yield a pharmacologic effect. The purpose of the phase 0 studies is to assist in the go versus no-go decision-making process of a drug's fate earlier in the development process, using relevant human models instead of relying on sometimes inconsistent animal data, thus helping to confirm endpoints such as mechanism of action, pharmacology, bioavailability and pharmacodynamics. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Completed |
NCT00729586 -
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT00756847 -
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
|
Phase 1 | |
| Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
| Completed |
NCT02017353 -
Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
|
Phase 2 | |
| Completed |
NCT00997373 -
Letrozole as a Treatment of Endometrial Cancer
|
N/A | |
| Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04576104 -
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06102252 -
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
|
N/A | |
| Active, not recruiting |
NCT02598219 -
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
|
Phase 3 | |
| Recruiting |
NCT04159155 -
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
| Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
| Suspended |
NCT06253494 -
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03917381 -
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
| Recruiting |
NCT06413992 -
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05316467 -
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
|
Phase 2/Phase 3 |